Rockefeller Capital Management L.P. Takes $1.39 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Rockefeller Capital Management L.P. purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 109,959 shares of the company’s stock, valued at approximately $1,385,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management raised its position in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares in the last quarter. Intech Investment Management LLC grew its position in Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after acquiring an additional 1,159 shares in the last quarter. Hsbc Holdings PLC grew its position in Amneal Pharmaceuticals by 1.6% in the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Comerica Bank increased its stake in shares of Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 17.30% of the stock is owned by company insiders.

Amneal Pharmaceuticals Trading Down 2.0%

Shares of Amneal Pharmaceuticals stock opened at $16.97 on Thursday. The firm has a fifty day simple moving average of $14.04 and a 200-day simple moving average of $13.51. Amneal Pharmaceuticals, Inc. has a 1-year low of $7.66 and a 1-year high of $17.86. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of 44.66 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AMRX shares. UBS Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays raised their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.